Roivant Sciences ROIV
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$132.50M (5 inflow days, 15 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 42.3% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 4.24% to 6.30% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Frank Torti | Individual/Insider | 2026/Q4 | +11,996,640 | 1.7% |
| BlackRock | Mutual Fund | 2026/Q4 | +13,643,141 | 8.5% |
| Jennison Associates LLC | Mutual Fund | 2026/Q4 | +7,585,461 | 1.7% |
| Farallon Capital Management, L.L.C. | Hedge Fund | 2026/Q4 | +7,436,533 | 3.0% |
| J.P. Morgan Asset Management, Inc. | Mutual Fund | 2026/Q4 | +6,038,676 | 0.9% |
| State Street Global Advisors | Mutual Fund | 2026/Q4 | +4,603,612 | 3.1% |
| FMR | Mutual Fund | 2026/Q4 | +4,479,045 | 11.8% |
| Nearwater Capital Markets, Limited | Private Company | 2026/Q4 | +4,100,000 | 0.8% |
| Bank of America Corporation | Public Company | 2026/Q4 | +3,041,189 | 0.9% |
| Lord, Abbett & Co. LLC | Mutual Fund | 2026/Q4 | +1,657,032 | 0.3% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q4 | +1,508,914 | 3.7% |
| Rubric Capital Management LP | Hedge Fund | 2026/Q4 | +1,481,524 | 1.0% |
| Invesco Capital Management LLC | Mutual Fund | 2026/Q4 | +1,437,196 | 1.2% |
| Janus Henderson Group plc | Mutual Fund | 2026/Q4 | +1,285,041 | 0.6% |
| Rockefeller & Co. LLC | Mutual Fund | 2026/Q4 | +1,166,663 | 0.2% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 11 Nov 2026 | Frank Torti | President & Vant Chair | Sale to Issuer | -12,800 | $41.85 | 12,306,950 |
| 11 Nov 2026 | Mayukh Sukhatme | President, Chief Investment Officer & Director | Sale to Issuer | -1,737 | $41.85 | 386,602 |
| 11 Nov 2026 | Matthew Gline | Chief Executive Officer | Sale to Issuer | -1,600 | $41.85 | 426,077 |
| 11 Nov 2026 | Frank Torti | President & Vant Chair | Other Disposition | -1,176,143 | $42.01 | 12,306,950 |
| 11 Nov 2026 | Mayukh Sukhatme | President, Chief Investment Officer & Director | Other Disposition | -165,444 | $42.01 | 386,602 |
| 11 Nov 2026 | Matthew Gline | Chief Executive Officer | Other Disposition | -156,307 | $42.01 | 426,077 |
| 10 Nov 2026 | Richard Pulik | Chief Financial Officer | Open Market Disposition | -47,635 | $41.89 | 38,882 |
| 10 Nov 2026 | Richard Pulik | Chief Financial Officer | Derivative Exercise and Sale | -252,365 | $42.03 | 38,882 |
| 9 Nov 2026 | Frank Torti | President & Vant Chair | Intent to Sell (Form 144) | -1,234,964 | $41.08 | – |
| 9 Nov 2026 | Mayukh Sukhatme | President, Chief Investment Officer & Director | Intent to Sell (Form 144) | -173,725 | $41.00 | – |
| 9 Nov 2026 | Matthew Gline | Chief Executive Officer | Intent to Sell (Form 144) | -164,136 | $41.00 | – |
| 9 Nov 2026 | Richard Pulik | Chief Financial Officer | Intent to Sell (Form 144) | -125,000 | $41.20 | – |
| 9 Nov 2026 | Eric Venker | President & CEO of Immunovant | Open Market Disposition | -187,943 | $41.00 | 585,552 |
| 2 Nov 2026 | Eric Venker | President & CEO of Immunovant | Open Market Disposition | -200,000 | $36.31 | 773,495 |
| 27 Oct 2026 | Eric Venker | President & CEO of Immunovant | Automatic Disposition | -200,000 | $36.59 | 973,495 |
| 22 Oct 2026 | James Momtazee | Independent Director | Sale to Issuer | -77 | $36.49 | 107,211 |
| 22 Oct 2026 | James Momtazee | Independent Director | Other Acquisition | +383 | – | 107,211 |
| 22 Oct 2026 | Melissa Epperly | Independent Director | Sale to Issuer | -116 | $36.49 | 10,297 |
| 22 Oct 2026 | Melissa Epperly | Independent Director | Other Acquisition | +513 | – | 10,297 |
| 22 Oct 2026 | Ilan Oren | Independent Chairperson | Other Acquisition | +810 | – | 119,436 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 45,513,591 | 6.3% | 6.1 |
| 15 Oct 2026 | 40,302,998 | 5.6% | 7.9 |
| 30 Sep 2026 | 39,296,630 | 5.4% | 4.4 |
| 15 Sep 2026 | 36,181,548 | 5.0% | 4.1 |
| 31 Aug 2026 | 33,522,300 | 4.6% | 3.8 |
| 14 Aug 2026 | 30,601,726 | 4.2% | 5.0 |
No comments yet — be the first to weigh in on ROIV.
Sign in to join the discussion.